Cargando…
Antibody Correlates of Protection for COVID-19 Convalescent Plasma Associated with Reduced Outpatient Hospitalizations
SARS-CoV-2 antibody levels associated with reduced hospitalization risk remain undefined. Our outpatient COVID-19 convalescent plasma (CCP), placebo-controlled trial observed SARS-CoV-2 antibody levels decreasing 22-fold from matched donor units into post-transfusion seronegative recipients. Unvacci...
Ejemplares similares
-
How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?
por: Bloch, Evan M., et al.
Publicado: (2022) -
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2022) -
Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2021) -
Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study
por: Zhu, Xianming, et al.
Publicado: (2023) -
Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial
por: Baksh, Sheriza N, et al.
Publicado: (2023)